research use only

PLVAP/PV-1 Antibody [E23J22]

Cat.No.: F2799

Application: Reactivity: Mouse

Usage Information

Dilution
IHC1:1000 IF1:1000 FCM1:10000

Application
IHC, IF, FCM

Reactivity
Mouse

Source
Rat Monoclonal Antibody

Storage Buffer
PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3

Storage (from the date of receipt)
-20°C (avoid freeze-thaw cycles), 2 years

Datasheet & SDS

Biological Description

Specificity
PLVAP/PV-1 Antibody [E23J22] detects endogenous levels of total PLVAP/PV-1 protein.

Clone
E23J22

Synonym(s)
Pv1; Plasmalemma vesicle-associated protein; MECA-32 antigen; Plasmalemma vesicle protein 1; PV-1

Background
PLVAP (PV-1, plasmalemma vesicle-associated protein) is a type II transmembrane glycoprotein selectively expressed in fenestrated endothelia of kidney glomeruli, intestinal villi, liver sinusoids, and tumor neovasculature, but absent from the blood-brain barrier and continuous vessels, that organizes stomatal and fenestral diaphragms via its ~390-residue C-terminal extracellular coiled-coil domain. This domain forms rigid, parallel α-helical homodimers stabilized by five interchain disulfide bonds (Cys142, Cys153, Cys178, Cys199, Cys224), radiating as 8–10 spoke-like fibers spanning caveolar necks or fenestrae with precise 10–15 nm geometry. Functioning as a molecular sieve, PLVAP selectively restricts plasma protein transcytosis through caveolae and transendothelial channels, establishing a cutoff that allows passage of albumin and IgG while blocking larger complexes. VEGF/PI3K/p38MAPK signaling transcriptionally induces PLVAP during angiogenesis to widen caveolar openings and increase diaphragm density, which paradoxically enhances paracellular leakage via endothelial contractility. Genetic ablation of PLVAP results in 2–3-fold enlarged caveolae, loss of diaphragms, protein-losing enteropathy, hypoproteinemia, hypertriglyceridemia, and neonatal lethality from circulatory collapse, underscoring its essential role in maintaining basal permeability restriction. PLVAP is upregulated by hypoxia and VEGF, marking leaky tumor microvasculature that facilitates metastasis, and mediates vasogenic edema and leukocyte diapedesis in ischemia and sepsis.

Background

PLVAP (PV-1, plasmalemma vesicle-associated protein) is a type II transmembrane glycoprotein selectively expressed in fenestrated endothelia of kidney glomeruli, intestinal villi, liver sinusoids, and tumor neovasculature, but absent from the blood-brain barrier and continuous vessels, that organizes stomatal and fenestral diaphragms via its ~390-residue C-terminal extracellular coiled-coil domain. This domain forms rigid, parallel α-helical homodimers stabilized by five interchain disulfide bonds (Cys142, Cys153, Cys178, Cys199, Cys224), radiating as 8–10 spoke-like fibers spanning caveolar necks or fenestrae with precise 10–15 nm geometry. Functioning as a molecular sieve, PLVAP selectively restricts plasma protein transcytosis through caveolae and transendothelial channels, establishing a cutoff that allows passage of albumin and IgG while blocking larger complexes. VEGF/PI3K/p38MAPK signaling transcriptionally induces PLVAP during angiogenesis to widen caveolar openings and increase diaphragm density, which paradoxically enhances paracellular leakage via endothelial contractility. Genetic ablation of PLVAP results in 2–3-fold enlarged caveolae, loss of diaphragms, protein-losing enteropathy, hypoproteinemia, hypertriglyceridemia, and neonatal lethality from circulatory collapse, underscoring its essential role in maintaining basal permeability restriction. PLVAP is upregulated by hypoxia and VEGF, marking leaky tumor microvasculature that facilitates metastasis, and mediates vasogenic edema and leukocyte diapedesis in ischemia and sepsis.

References
https://pubmed.ncbi.nlm.nih.gov/36996108/ https://pubmed.ncbi.nlm.nih.gov/15155804/

Reference Table for Selecting PVDF Membrane Pore Size Specifications

Protein Size (kDa)	PVDF Transfer Membrane Pore Size (μm)
< 10	0.22
10-20	0.22
20-30	0.45
30-45	0.45
45-70	0.45
80-100	0.45
100-140	0.45
> 140	0.45

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Protein Size (kDa)	Separating Gel Percentage
4-40	20%
12-45	15%
10-70	12.5%
15-100	10%
25-100	8%
60-210	5%